Lv1
38 积分 2023-07-04 加入
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
13天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
13天前
已完结
Antibody–drug conjugates come of age in oncology
1个月前
已完结
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
6个月前
已完结
FDA approvals in 2024: new options for patients across cancer types and therapeutic classes
8个月前
已完结
IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy
9个月前
已完结
Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease
9个月前
已完结
A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer
10个月前
已完结
皖公网安备34019202002308
